Fresh analysis suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional diet and exercise plans.
Research printed in a major health publication demonstrates that while obese people can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"People buying such drugs must be aware of the danger of fast weight regain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass within about 18 months.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of patients, compared the results of the injectable medications with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone typically experience a more gradual creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Doctors believe the way of the jabs is key to understanding the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the therapy should be considered ongoing.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the long-term character of excess weight," similar to managing diseases like hypertension.
Patient Experiences
Users who have come off the medication describe a sudden return of cravings.
"It felt as if a switch that goes on and I was suddenly starving," said a patient.
This difficulty is compounded if patients have not developed sustainable dietary or behavioural changes during therapy.
Significant Adoption
Survey data indicate that a significant number of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is greater among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on ongoing behavioural changes.
